Granted Both Orphan Drug & Fast Track designations for Amezalpat (TPST-1120) for the treatment of patients with Hepatocellular Carcinoma ...

Statins, commonly used to lower cholesterol, may significantly reduce the risk of liver cancer in patients with chronic liver disease, a new study suggests. Researchers found that statin use decreased ...

In a US retrospective study of data on veterans with compensated cirrhosis, more than half progressed to complications after approximately 5 years.

Research published in JAMA Internal Medicine reveals statins may reduce liver cancer risk by 33% and liver complications by ...

People who used lipophilic (fat-soluble) statins like atorvastatin and simvastatin had the greatest outcomes and ...

Hepatocellular carcinoma (HCC) represents about 90% of all cases of liver cancer and has a poor prognosis, with a 5-year survival rate of about 18%. Previous findings had shown that RNA ...

Inclusion of female and Hispanic/Latino patients has increased over time, but most trials of metabolic dysfunction-associated ...

Discover how statin use in chronic liver disease lowers liver cancer and decompensation risks, with added benefits from ...

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization ...

Jiangsu Hengrui Pharmaceuticals and its partner Elevar Therapeutics will have to wait even longer before their PD-1 inhibitor ...

Despite resubmitting after an initial complete response letter (CRL) due to manufacturing issues, the combination therapy ...

Discover how Yttrium-90 radioembolisation may offer improved survival for large hepatocellular carcinoma tumours compared to ...